Navigation überspringen
Universitätsbibliothek Heidelberg
Trefferliste Zurück zur Trefferübersicht und Suche
disk Markieren   Persönliche Notiz
Drucker
Andere Formate
Exportieren/Zitieren
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Scheiner, Bernhard [VerfasserIn]   i
 Pomej, Katharina [VerfasserIn]   i
 Kirstein, Martha M. [VerfasserIn]   i
 Hucke, Florian [VerfasserIn]   i
 Finkelmeier, Fabian [VerfasserIn]   i
 Waidmann, Oliver [VerfasserIn]   i
 Himmelsbach, Vera [VerfasserIn]   i
 Schulze, Kornelius [VerfasserIn]   i
 von Felden, Johann [VerfasserIn]   i
 Fründt, Thorben W. [VerfasserIn]   i
 Stadler, Marc [VerfasserIn]   i
 Heinzl, Harald [VerfasserIn]   i
 Shmanko, Kateryna [VerfasserIn]   i
 Spahn, Stephan [VerfasserIn]   i
 Radu, Pompilia [VerfasserIn]   i
 Siebenhüner, Alexander R. [VerfasserIn]   i
 Mertens, Joachim C. [VerfasserIn]   i
 Rahbari, Nuh Nabi [VerfasserIn]   i
 Kütting, Fabian [VerfasserIn]   i
 Waldschmidt, Dirk-Thomas [VerfasserIn]   i
 Ebert, Matthias [VerfasserIn]   i
 Teufel, Andreas [VerfasserIn]   i
 De Dosso, Sara [VerfasserIn]   i
 Pinato, David J. [VerfasserIn]   i
 Pressiani, Tiziana [VerfasserIn]   i
 Meischl, Tobias [VerfasserIn]   i
 Balcar, Lorenz [VerfasserIn]   i
 Müller, Christian [VerfasserIn]   i
 Mandorfer, Mattias [VerfasserIn]   i
 Reiberger, Thomas [VerfasserIn]   i
 Trauner, Michael [VerfasserIn]   i
 Personeni, Nicola [VerfasserIn]   i
 Rimassa, Lorenza [VerfasserIn]   i
 Bitzer, Michael [VerfasserIn]   i
 Trojan, Jörg [VerfasserIn]   i
 Weinmann, Arndt [VerfasserIn]   i
 Wege, Henning [VerfasserIn]   i
 Dufour, Jean-François [VerfasserIn]   i
 Peck-Radosavljevic, Markus [VerfasserIn]   i
 Vogel, Arndt [VerfasserIn]   i
 Pinter, Matthias [VerfasserIn]   i
Titel:Prognosis of patients with hepatocellular carcinoma treated with immunotherapy
Titelzusatz:development and validation of the CRAFITY score
Verf.angabe:Bernhard Scheiner, Katharina Pomej, Martha M. Kirstein, Florian Hucke, Fabian Finkelmeier, Oliver Waidmann, Vera Himmelsbach, Kornelius Schulze, Johann von Felden, Thorben W. Fründt, Marc Stadler, Harald Heinzl, Kateryna Shmanko, Stephan Spahn, Pompilia Radu, Alexander R. Siebenhüner, Joachim C. Mertens, Nuh N. Rahbari, Fabian Kütting, Dirk-Thomas Waldschmidt, Matthias P. Ebert, Andreas Teufel, Sara De Dosso, David J. Pinato, Tiziana Pressiani, Tobias Meischl, Lorenz Balcar, Christian Müller, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Nicola Personeni, Lorenza Rimassa, Michael Bitzer, Jörg Trojan, Arndt Weinmann, Henning Wege, Jean-François Dufour, Markus Peck-Radosavljevic, Arndt Vogel, Matthias Pinter
E-Jahr:2022
Jahr:February 2022
Umfang:12 S.
Fussnoten:Online verfügbar: 12. Oktober 2021, Artikelversion: 14. Januar 2022 ; Gesehen am 27.05.2024
Titel Quelle:Enthalten in: Journal of hepatology
Ort Quelle:Amsterdam [u.a.] : Elsevier Science, 1985
Jahr Quelle:2022
Band/Heft Quelle:76(2022), 2 vom: Feb., Seite 353-363
ISSN Quelle:1600-0641
Abstract:Background & Aims - Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need. - Methods - Patients with HCC put on PD-(L)1-based immunotherapy were included in a training set (n = 190; 6 European centers) and a validation set (n = 102; 8 European centers). We investigated the prognostic value of baseline variables on overall survival using a Cox model in the training set and developed the easily applicable CRAFITY (CRP and AFP in ImmunoTherapY) score. The score was validated in the independent, external cohort, and evaluated in a cohort of patients treated with sorafenib (n = 204). - Results - Baseline serum alpha-fetoprotein ≥100 ng/ml (hazard ratio [HR] 1.7; p = 0.007) and C-reactive protein ≥1 mg/dl (HR, 1.7; p = 0.007) were identified as independent prognostic factors in multivariable analysis and were used to develop the CRAFITY score. Patients who fulfilled no criterion (0 points; CRAFITY-low) had the longest median overall survival (27.6 (95% CI 19.5-35.8) months), followed by those fulfilling 1 criterion (1 point; CRAFITY-intermediate; 11.3 (95% CI 8.0-14.6) months), and patients meeting both criteria (2 points; CRAFITY-high; 6.4 (95% CI 4.8-8.1) months; p <0.001). Additionally, best radiological response (complete response/partial response/stable disease/progressive disease) was significantly better in patients with lower CRAFITY score (CRAFITY-low: 9%/20%/52%/20% vs. CRAFITY-intermediate: 3%/25%/36%/36% vs. CRAFITY-high: 2%/15%/22%/61%; p = 0.003). These results were confirmed in the independent validation set and in different subgroups, including Child-Pugh A and B, performance status 0 and ≥1, and first-line and later lines. In the sorafenib cohort, CRAFITY was associated with survival, but not radiological response. - Conclusions - The CRAFITY score is associated with survival and radiological response in patients receiving PD-(L)1 immunotherapy. The score may help with patient counseling but requires prospective validation. - Lay summary - The immunotherapy-based regimen of atezolizumab plus bevacizumab represents the new standard of care in systemic first-line therapy of hepatocellular carcinoma (HCC). Biomarkers to predict treatment outcome are an unmet need in patients undergoing immunotherapy for HCC. We developed and externally validated a score that predicts outcome in patients with HCC undergoing immunotherapy with immune checkpoint blockers.
DOI:doi:10.1016/j.jhep.2021.09.035
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1016/j.jhep.2021.09.035
 kostenfrei: Volltext: https://www.sciencedirect.com/science/article/pii/S0168827821021000
 DOI: https://doi.org/10.1016/j.jhep.2021.09.035
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:alpha-fetoprotein
 C-reactive protein
 immune checkpoint inhibitor
 liver cancer
K10plus-PPN:1889869651
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69217587   QR-Code

zum Seitenanfang

© Universitätsbibliothek HeidelbergMailImpressum / Datenschutz   Design